Breaking News Instant updates and real-time market news.

MRK

Merck

$63.85

1.075 (1.71%)

, BMY

Bristol-Myers

$49.91

-5.52 (-9.96%)

13:50
10/10/16
10/10
13:50
10/10/16
13:50

Bristol-Myers falls as Merck upstages with new lung cancer data

Merck (MRK) and Bristol-Myers (BMY) are in focus Monday after the biopharmaceutical giants reported divergent success rates for their respective lung cancer therapies at this weekend's meeting of the European Society for Medical Oncology, or ESMO, leading a number of Wall Street analysts to argue that Merck may have sealed its lung cancer leadership position for some time to come. MERCK DATA: In what was perhaps the most heavily-discussed data at ESMO 2016, Merck reported results from the "KEYNOTE-024" and "KEYNOTE-021" studies of its lead cancer drug Keytruda as a first-line treatment in non-small cell lung cancer, the most common form of the disease. KEYNOTE-024 evaluated patients whose cancers expressed high levels of the molecule PD-L1, indicating potentially strong receptiveness to Keytruda, and results showed that the drug reduced the risk of cancer progression or death by 50% relative to chemotherapy, achieving a median delay in disease progression of 10.3 months as compared to chemotherapy's 6 months. Keytruda also generated a 40% reduction in risk of death compared to chemotherapy, and shrank tumors in 44.8% of patients -- including six who achieved total cancer absence -- as compared to the 27.8% who saw tumor reduction with chemo. Separately, Merck reported data from a subgroup of KEYNOTE-021 patients whose lung cancer had spread to nearby organs and whose tumors did not necessarily have high levels of PD-L1. Data showed that 55% of Keytruda-plus-chemo patients achieved tumor reduction as compared to 29% of chemo patients, and the drug also delayed disease progression by 13 months as compared to the 8.9 months achieved by chemotherapy alone, though overall patient survival did not meaningfully diverge as of the data cut-off. BRISTOL-MYERS DATA: Bristol-Myers Squibb, meanwhile, gave a final analysis of CheckMate-026, its trial of Opdivo as a first-line treatment in non-small cell lung cancer patients with at least a minimum expression of PD-L1. The company had disclosed in early August that the trial failed to meet its primary endpoint of delaying disease progression, and details presented at ESMO showed that median disease delay was 4.2 months with Opdivo as compared to 5.9 months with chemotherapy. Overall patient survival was 14.4 months, slightly better than the 13.2 months achieved by chemo. GOLDMAN SAYS CLEAR WIN FOR MERCK: After this weekend's presentations, Goldman Sachs analyst Jami Rubin raised her price target on Merck to $70 from $65, calling it the "clear winner" at the show. The KEYNOTE-024 results are "practice changing" and a majority of patients with high PD-L1 expression, representing about 25%-30% of the first-line lung cancer market, or more than $3B, will likely be put on Keytruda, Rubin says. In the low-expressor population, however, "the battle rages on" as KEYNOTE-021 showed "compelling" but inconclusive results, says Rubin. She also raises the question of how long Merck can retain leadership if new immunotherapies show superior results next year. LEERINK SAYS KEYTRUDA STEALS SHOW: Leerink analyst Seamus Fernandez says Keytruda stole the show, with the KEYNOTE-024 data now appearing to support Merck's prediction of a "sea change" in treating high PD-L1 expressors. The "nearly inexplicable" failure of Bristol's CheckMate-026 puts Merck "in the driver's seat" of first-line lung cancer treatment for at least 12-18 months, though it will likely command a long-term presence in the space given the "stunning" Keytruda data, the analyst says. Fernandez also argues that the KEYNOTE-021 data "raises the possibility" that Merck could compete more broadly in the non-squamous market, though significant follow-up data would be required. PRICE ACTION: Shares of Bristol-Myers dipped about 10% Monday, while Merck is up 1.8% to $63.90 per share. OTHERS TO WATCH: Other biopharmaceutical companies in focus after presentations at ESMO 2016 and the World Muscle Society Congress include OncoMed (OMED), Novartis (NVS), Biogen (BIIB), AveXis (AVXS) and TESARO (TSRO), which has surged a notable 20% after reporting positive Phase 3 data on its ovarian cancer therapy, niraparib.

MRK

Merck

$63.85

1.075 (1.71%)

BMY

Bristol-Myers

$49.91

-5.52 (-9.96%)

OMED

OncoMed

$11.34

0.08 (0.71%)

NVS

Novartis

$77.72

-0.57 (-0.73%)

BIIB

Biogen

$305.59

-0.4 (-0.13%)

AVXS

AveXis

$47.51

2.35 (5.20%)

TSRO

TESARO

$99.26

-0.63 (-0.63%)

  • 10

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

  • 14

    Dec

  • 11

    Jan

MRK Merck
$63.85

1.075 (1.71%)

10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
BMY Bristol-Myers
$49.91

-5.52 (-9.96%)

09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
OMED OncoMed
$11.34

0.08 (0.71%)

06/06/16
BMOC
06/06/16
NO CHANGE
BMOC
OncoMed data positive, says BMO Capital
BMO Capital believes that data on three of OncoMed's drugs remove the risk of their development. The firm thinks that the data could cause the company's partners, Bayer and GlaxoSmithKline, to exercise options, yielding $1034M in non-dilutive financing for OncoMed.
06/06/16
PIPR
06/06/16
NO CHANGE
Target $29
PIPR
Overweight
Piper says confidence in OncoMed increased by ASCO updates
Piper Jaffray analyst Edward Tenthoff noted that OncoMed presented new Phase Ib data from vantictumab and ipafricept at the ASCO meeting, adding that he was "particularly impressed" by early ipafricept signal in ovarian cancer. The analyst, who contends that OncoMed has a "rich pipeline" of seven cancer biotherapeutics in the clinic, keeps an Overweight rating and $29 price target on the stock.
09/22/16
HCWC
09/22/16
INITIATION
Target $20
HCWC
Buy
OncoMed initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak started OncoMed Pharmaceuticals (OMED) with a Buy rating and $20 price target. The company is entering a "year of dramatic changes" with upcoming opt-in decisions for its lead drug candidates expected from partners Celgene (CELG), Bayer (BAYRY) and GlaxoSmithKline (GSK), Deepak tells investors in a research note. The analyst believes the partnerships could payoff with long-term benefits.
04/28/16
PIPR
04/28/16
NO CHANGE
Target $29
PIPR
Overweight
Piper says AbbVie deal for Stemcentrx shows 'valuation disconnect' for OncoMed
Piper Jaffray analyst Edward Tenthoff said AbbVie's (ABBV) $5.8B deal for privately-held Stemcentrx is "another clear example of the valuation disconnect" at OncoMed (OMED), which he points has seven cancer biotherapeutics in the clinic, compared to Stemcentrx's five Phase I assets. Tenthoff reiterates an Overweight rating and $29 price target on OncoMed shares, which are up 21% to $14.20 in afternoon trading.
NVS Novartis
$77.72

-0.57 (-0.73%)

09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
09/20/16
CHDN
09/20/16
INITIATION
Target $95
CHDN
Buy
Novartis initiated with a Buy at Chardan
Chardan initiated Novartis with a Buy and a $95 price target.
BIIB Biogen
$305.59

-0.4 (-0.13%)

10/03/16
BMOC
10/03/16
NO CHANGE
Target $304
BMOC
Biogen potential trading opportunity into year-end, says BMO Capital
BMO Capital hosted a call with an expert on Alzheimers that may present a trading opportunity in Biogen (BIIB) shares as we approach sola Phase 3 and aducanumab titration data expected at year end. The expert said evidence supports the amyloid hypothesis of AD outweighs the evidence that undercuts it, but suggested that patient selection and trial design/execution key to demonstrating benefit to support regulatory approval. He estimated that Lilly's (LLY) EXPEDITION-3 trial has a ~60% probability of success, with Biogen's aducanumab greater than70% as long as rates of ARIA-E can be reduced with titration. Analyst Ian Somaiya believes positive Phase III Sola data could provide a positive read through to aducanumab and results in Biogen shares trading up 20-25%. If Sola misses, aducanumab's ability to clear beta amyloid oligomers & plaques and in our opinion a better trial design could limit downside in shares to approximately 10%. Somaiya rates Biogen a Market Perform with a $304 price target.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
10/04/16
RBCM
10/04/16
NO CHANGE
Target $375
RBCM
Outperform
Biogen could rise $20 or more per share on SMA success, says RBC Capital
RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.
10/10/16
WELS
10/10/16
NO CHANGE
WELS
Ionis drug likely to be approved rapidly, says Wells Fargo
After Ionis Pharmaceuticals (IONS) and partner Biogen (BIIB) reported detailed data for their RNA Therapeutic nusinersen, in patients with both symptomatic and pre-symptomatic type 1 Spinal Muscular Atrophy, as well as data for patients with type 2/3 Spinal Muscular Atrophy, or SMA, Wells Fargo says it expects the drug to be rapidly approved. The firm thinks that the FDA will approve "a broad label" covering pre-symptomatic and symptomatic type I SMA, as well as type 2/3 SMA. The firm says that the companies should have "a very large commercial opportunity," and it keeps an Outperform rating on Ionis.
AVXS AveXis
$47.51

2.35 (5.20%)

09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
10/06/16
GSCO
10/06/16
NO CHANGE
Target $71
GSCO
Buy
AveXis attractive acquisition target, price target to $71 at Goldman
Goldman analyst Salveen Richter said AveXis has two approaching catalysts coming up, the AVXS-101 update in SMA Type 1 at the World Muscle Society, or WMS, on October 8, and clarity on the AVXS-101 pivotal trial design in late October/early November. The analyst expects positive WMS data and raaised his probability of success to 60% from 45%. He expects compelling motor milestone data and pivotal trial visibility to make AveXis an attractive acquisition target and raised his price target to $71 from $46 on shares and reiterated his Buy rating.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/10/16
PIPR
10/10/16
NO CHANGE
Target $24
PIPR
Overweight
AveXis data bodes well for Audentes gene therapy program, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said additional data presented by AveXis (AVXS) from its ongoing Phase 1/2 trial in infantile-onset spinal muscular atrophy "augurs well" for Audentes Therapeutics' (BOLD) gene therapy program for X-linked myotubular myopathy, as he sees several points of similarity that provide a positive read-through though the companies are targeting different diseases. Schimmer, who does not have a rating on AveXis, reiterates his Overweight rating and $24 price target on Audentes shares.
TSRO TESARO
$99.26

-0.63 (-0.63%)

10/10/16
RAJA
10/10/16
NO CHANGE
Target $120
RAJA
Strong Buy
TESARO price target raised to $120 at Raymond James
Raymond James analyst Christopher Raymond raised TESARO's price target to $120 from $105 fter the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Raymond thinks niraparib will have a broad ovarian cancer label and corresponding market opportunity and reiterates his Strong Buy rating.
10/10/16
FBCO
10/10/16
NO CHANGE
Target $122
FBCO
Outperform
TESARO price target raised to $122 on Niraparib data at Credit Suisse
Credit Suisse analyst Alethia Young raised TESARO's price target to $122 from $90 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. The analyst thinks niraparib has broad effects across the 2nd line ovarian population and would expect the label is broad. Young has an Outperform ratting n TESARO shares.
10/10/16
RAJA
10/10/16
NO CHANGE
Target $120
RAJA
Outperform
TESARO price target raised to $120 from $105 at Raymond James
Raymond James analyst Christopher Raymond raised TESARO's price target to $120 from $105 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Raymond thinks niraparib will have a broad ovarian cancer label and corresponding market opportunity and reiterates his Strong Buy rating
10/10/16
RBCM
10/10/16
NO CHANGE
RBCM
TESARO price target raised to $128 from $122 at RBC Capital
RBC Capital analyst Adnan Butt raised his price target on TESARO after ovarian cancer patients taking the company's Niraparib drug responded better than expected. Butt said that the drug benefited the patients regardless of BRCA or HRD biomarker status. He keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

, CSCO

Cisco

$30.06

0.11 (0.37%)

18:32
12/09/16
12/09
18:32
12/09/16
18:32
Hot Stocks
Arista Networks favored in ITC initial determination on four of six patents »

Arista Networks (ANET)…

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

CSCO

Cisco

$30.06

0.11 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

TKTDY

Takata Corporation

$10.70

0.05 (0.47%)

18:22
12/09/16
12/09
18:22
12/09/16
18:22
Periodicals
U.S. DOT looks to accelerate pace of Takata air bag replacements, Reuters says »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DV

DeVry

$31.90

0.9 (2.90%)

18:17
12/09/16
12/09
18:17
12/09/16
18:17
Hot Stocks
Breaking Hot Stocks news story on DeVry »

International Value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

18:10
12/09/16
12/09
18:10
12/09/16
18:10
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Cornerstone OnDemand has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$0.12

-0.0014 (-1.17%)

18:03
12/09/16
12/09
18:03
12/09/16
18:03
Hot Stocks
NYSE MKT says CEL-SCI noncompliant with certain listing requirements »

CEL-SCI reported on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$89.00

0.68 (0.77%)

18:01
12/09/16
12/09
18:01
12/09/16
18:01
Periodicals
Exxon CEO Tillerson emerges as top candidate for secretary of state, WSJ says »

Exxon Mobil CEO Rex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$50.36

0.05 (0.10%)

17:58
12/09/16
12/09
17:58
12/09/16
17:58
Hot Stocks
H.B. Fuller announces restructuring, to eliminate, relocate 220 positions »

H.B. Fuller has announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$287.77

-1.77 (-0.61%)

17:53
12/09/16
12/09
17:53
12/09/16
17:53
Periodicals
Biogen looks like a bargain, Barron's reports »

Biogen trades at just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$40.40

0.63 (1.58%)

17:42
12/09/16
12/09
17:42
12/09/16
17:42
Periodicals
Sanofi to lay off 20% of U.S. diabetes, cardiovascular staff, Bloomberg says »

The layoffs include parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

17:38
12/09/16
12/09
17:38
12/09/16
17:38
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Investor Praesidium said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TACO

Del Taco

$14.75

-0.39 (-2.58%)

17:34
12/09/16
12/09
17:34
12/09/16
17:34
Hot Stocks
Breaking Hot Stocks news story on Del Taco »

PW Acquisitions cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 09

    Jan

  • 09

    Dec

UNVR

Univar

$26.36

0.54 (2.09%)

, BXLT

Baxalta

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Univar names Eric Foster chief information officer »

Univar (UNVR) named Eric…

UNVR

Univar

$26.36

0.54 (2.09%)

BXLT

Baxalta

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PARN

Parnell

$1.42

-0.0031 (-0.22%)

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Breaking Hot Stocks news story on Parnell 

Parnell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$20.81

0.2 (0.97%)

, NVRO

Nevro

$76.38

-1.88 (-2.40%)

17:24
12/09/16
12/09
17:24
12/09/16
17:24
Hot Stocks
Boston Scientific files patent infringement suit against Nevro »

Nevro (NVRO) announced…

BSX

Boston Scientific

$20.81

0.2 (0.97%)

NVRO

Nevro

$76.38

-1.88 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RTN

Raytheon

$146.30

0.14 (0.10%)

17:21
12/09/16
12/09
17:21
12/09/16
17:21
Hot Stocks
Raytheon awarded $101.9M government contract »

Raytheon Co., Goleta,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$8.77

-0.16 (-1.79%)

17:18
12/09/16
12/09
17:18
12/09/16
17:18
Hot Stocks
CEMEX receives subpoena from SEC regarding Foreign Corrupt Practices Act »

On December 9, 2016,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDEX

PRO-DEX

$4.48

0.034 (0.76%)

17:06
12/09/16
12/09
17:06
12/09/16
17:06
Syndicate
Breaking Syndicate news story on PRO-DEX »

PRO-DEX files $25M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFBX

Peoples Financial

$14.50

-0.5 (-3.33%)

17:02
12/09/16
12/09
17:02
12/09/16
17:02
Hot Stocks
Breaking Hot Stocks news story on Peoples Financial »

Jeffrey L. Gendell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QUIK

QuickLogic

$0.94

-0.0163 (-1.71%)

17:00
12/09/16
12/09
17:00
12/09/16
17:00
Syndicate
Breaking Syndicate news story on QuickLogic »

QuickLogic files $40M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STRZA

Starz

17:00
12/09/16
12/09
17:00
12/09/16
17:00
Hot Stocks
Breaking Hot Stocks news story on Starz »

Elliott Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEL

Belmond

16:55
12/09/16
12/09
16:55
12/09/16
16:55
Syndicate
Breaking Syndicate news story on Belmond »

Belmond files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PARN

Parnell

$1.42

-0.0031 (-0.22%)

16:55
12/09/16
12/09
16:55
12/09/16
16:55
Hot Stocks
Breaking Hot Stocks news story on Parnell »

Parnell trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$43.73

0.15 (0.34%)

, SHAK

Shake Shack

$38.08

0.82 (2.20%)

16:50
12/09/16
12/09
16:50
12/09/16
16:50
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Shake Shack »

Morgan Stanley reports…

MS

Morgan Stanley

$43.73

0.15 (0.34%)

SHAK

Shake Shack

$38.08

0.82 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

MS

Morgan Stanley

$43.73

0.15 (0.34%)

, LXFT

Luxoft

$54.40

-1.8 (-3.20%)

16:44
12/09/16
12/09
16:44
12/09/16
16:44
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Luxoft »

Morgan Stanley reports…

MS

Morgan Stanley

$43.73

0.15 (0.34%)

LXFT

Luxoft

$54.40

-1.8 (-3.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$50.36

0.05 (0.10%)

16:44
12/09/16
12/09
16:44
12/09/16
16:44
Hot Stocks
H.B. Fuller announces restructuring plan »

On December 7, H.B.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.